International Clinical Trial: A randomised phase II study of limertinib and bevacizumab versus limertinib alone as second-line targeted treatment in locally advanced or metastatic NSCLC with EGFR mutations and resistance to third-generation EGFR-TKIs

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119645) titled 'A randomised phase II study of limertinib and bevacizumab versus limertinib alone as second-line targeted treatment in locally advanced or metastatic NSCLC with EGFR mutations and resistance to third-generation EGFR-TKIs' on March 2.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Anhui Chest Hospital

Condition: Non-small cell lung cancer, NSCLC

Intervention: Single drug group:Limertinib

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-03-15

Target Sample Size: Single drug group:20;Combination group:20;

Countries of Recruitment: China

To know mo...